Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 3
1989 1
1992 1
2002 2
2003 1
2011 2
2012 4
2015 2
2017 1
2018 4
2021 2
2022 5
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
Roehlen N, Muller M, Nehme Z, Crouchet E, Jühling F, Del Zompo F, Cherradi S, Duong FHT, Almeida N, Saviano A, Fernández-Vaquero M, Riedl T, El Saghire H, Durand SC, Ponsolles C, Oudot MA, Martin R, Brignon N, Felli E, Pessaux P, Lallement A, Davidson I, Bandiera S, Thumann C, Marchand P, Moll S, Nicolay B, Bardeesy N, Hoshida Y, Heikenwälder M, Iacone R, Toso A, Meyer M, Elson G, Schweighoffer T, Teixeira G, Zeisel MB, Laquerriere P, Lupberger J, Schuster C, Mailly L, Baumert TF. Roehlen N, et al. Among authors: lallement a. J Hepatol. 2023 Feb;78(2):343-355. doi: 10.1016/j.jhep.2022.10.011. Epub 2022 Oct 27. J Hepatol. 2023. PMID: 36309131 Free article.
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.
Roehlen N, Saviano A, El Saghire H, Crouchet E, Nehme Z, Del Zompo F, Jühling F, Oudot MA, Durand SC, Duong FHT, Cherradi S, Gonzalez Motos V, Almeida N, Ponsolles C, Heydmann L, Ostyn T, Lallement A, Pessaux P, Felli E, Cavalli A, Sgrignani J, Thumann C, Koutsopoulos O, Fuchs BC, Hoshida Y, Hofmann M, Vyberg M, Viuff BM, Galsgaard ED, Elson G, Toso A, Meyer M, Iacone R, Schweighoffer T, Teixeira G, Moll S, De Vito C, Roskams T, Davidson I, Heide D, Heikenwälder M, Zeisel MB, Lupberger J, Mailly L, Schuster C, Baumert TF. Roehlen N, et al. Among authors: lallement a. Sci Transl Med. 2022 Dec 21;14(676):eabj4221. doi: 10.1126/scitranslmed.abj4221. Epub 2022 Dec 21. Sci Transl Med. 2022. PMID: 36542691
Survey on deep learning for radiotherapy.
Meyer P, Noblet V, Mazzara C, Lallement A. Meyer P, et al. Among authors: lallement a. Comput Biol Med. 2018 Jul 1;98:126-146. doi: 10.1016/j.compbiomed.2018.05.018. Epub 2018 May 17. Comput Biol Med. 2018. PMID: 29787940 Review.
Super-enhancer-driven expression of BAHCC1 promotes melanoma cell proliferation and genome stability.
Berico P, Nogaret M, Cigrang M, Lallement A, Vand-Rajabpour F, Flores-Yanke A, Gambi G, Davidson G, Seno L, Obid J, Vokshi BH, Le Gras S, Mengus G, Ye T, Cordero CF, Dalmasso M, Compe E, Bertolotto C, Hernando E, Davidson I, Coin F. Berico P, et al. Among authors: lallement a. Cell Rep. 2023 Nov 28;42(11):113363. doi: 10.1016/j.celrep.2023.113363. Epub 2023 Nov 3. Cell Rep. 2023. PMID: 37924516 Free article.
Twenty years of HFA pMDI patents: facts and perspectives.
Rogueda P, Lallement A, Traini D, Iliev I, Young PM. Rogueda P, et al. Among authors: lallement a. J Pharm Pharmacol. 2012 Sep;64(9):1209-16. doi: 10.1111/j.2042-7158.2011.01387.x. Epub 2011 Nov 10. J Pharm Pharmacol. 2012. PMID: 22881434 Review.
[Restraint during care: The legal aspects].
Dupont M, Lallement A. Dupont M, et al. Among authors: lallement a. Soins. 2024 Jan-Feb;69(882):16-19. doi: 10.1016/j.soin.2023.12.004. Epub 2024 Jan 11. Soins. 2024. PMID: 38296414 Free article. French.
32 results